Downstream processing typically accounts for 60–80% of production costs. For IgG-X, the team implemented:
During the low pH elution step (0.1 M sodium citrate, pH 3.5), the aggregation issue flagged earlier emerged. Mab-A formed 15% aggregates post-elution.
The is a landmark document released in 2009 by the CMC Biotech Working Group . It serves as a comprehensive guide for applying Quality by Design (QbD) principles to the development of a monoclonal antibody (mAb). 1. Core Principles of the Study A Mab A Case Study In Bioprocess Development
Once the cell line is selected, the focus shifts to Upstream Processing (USP). This involves scaling the culture from a few milliliters in a shake flask to thousands of liters in a stainless steel or single-use bioreactor.
A bioprocess is only successful if the resulting protein is functional and safe. Analytical testing for mAb A focused on: The is a landmark document released in 2009
For mAb A, Chinese Hamster Ovary (CHO) cells were selected due to their ability to perform human-like post-translational modifications. Developers used a site-specific integration approach to ensure the gene of interest was inserted into a "hot spot" of high transcriptional activity, minimizing clonal variation. Media Optimization
Before clinical Phase III, the team performed using design of experiments (DoE). Critical process parameters (CPPs) and critical quality attributes (CQAs) were mapped. For example: Core Principles of the Study Once the cell
The study breaks down mAb production into four primary technical phases: Cell Line Development